Moreover, the overexpression of certain CYPs, such as CYP1B1, in some cancer cells has led to the development of CYP inhibitors for chemoprevention as well as chemotherapy prodrugs designed to be activated by CYPs specifically expressed in cancer cells for cell-specific cytotoxic effects, further demonstrating the potential for targeted cancer treatments utilizing CYP enzymes (Bruno and Njar, 2007). This evidence concerns the gene PPIG and cancer.